Home — MORU Tropical Health Network

Africa malaria resists key drug

Millions of lives at risk unless urgent action taken to stop drug-resistant malaria spreading in Africa

Patient-centred research is the core of our research activities, spanning 5 research units and over 50 research sites in Asia and Africa.

Billions of people live in malaria endemic countries; we aim to improve health through research that addresses this threat.

Paying attention to the public and communities is essential to make our programmes ethical and trustworthy, to maximise their success and impact.

Greater participation and inclusivity, as well as recognising the value of diversity, lead to fairer opportunities to fulfil everybody's potential.

The global fight against malaria has hit a critical point in Africa, where parasites resistant to artemisinin have emerged.

More interviews

New WHO classification of genetic variants causing G6PD deficiency
Posted 04/09/2024. Over 50 years after its first publication, this revised classification of G6PD genetic variants is the result of the 2022 WHO Global Malaria Programme experts’ consultation led by Professor Lucio Luzzatto. The new classification reconciles biochemical and clinical aspects of the different G6PD mutations and provides a reliable reference for scientists and clinicians. By Germana Bancone.